Association of ADT and EBRT
Phase 2Small molecule
Association of ADT and EBRT is one of 51 small molecule programs targeting Lung Cancer. It is currently in Phase 2.
2
Indications
6
Total Trials
5
Active Trials
50
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1399 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1Novantrone
PfizerPreclinical
Mekinist
NovartisPreclinical
Association of ADT and EBRT
IInstitut Bergonié
Phase 2
Viagra
VViatris Specialty LLC
Preclinical
Duragesic
CCephalon
Preclinical
Ranexa
MMenarini International Operations Luxembourg SA
Preclinical
Triptorelin Pamoate
IpsenPreclinical
Ifex
BBaxter Healthcare Corporation
Preclinical
Xylocaine
CCitius Pharmaceuticals, Inc.
Preclinical
Statin
Bristol-Myers SquibbPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Patients With Advanced Solid Tumors1 trial
Lung Cancer1 trial
Metastatic Soft-tissue Sarcoma1 trial
Advanced Sarcoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Association of ADT and EBRT. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- IInstitut Bergonié